Expands Scientific Advisory Board with Appointment of Prof. David
Spring
CAMBRIDGE, England–(BUSINESS WIRE)–Nanna Therapeutics Ltd, a biotechnology company developing novel drugs
to combat age-related diseases, particular those caused by mitochondrial
dysfunction, today announced that it had been awarded funding from
Innovate UK totalling £829,892 to apply its ground-breaking nanoscale
medicines discovery engine to develop novel disease modulating drugs.
Nanna Therapeutics’ discovery engine has the potential to deliver a
paradigm shift in the speed, efficiency and quality of drug discovery.
The significant time and cost savings associated with Nanna’s approach
could deliver cost-effective medicines rapidly, aligning with the
emerging needs and healthcare costs associated with an aging population.
It also means treating rare and segmented diseases has the potential to
become a commercially-viable reality, such as Nanna’s lead program
targeting MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and
Stroke-like episodes), a severe, life-limiting mitochondrial disorder
with no effective medicine available to patients.
Nanna Therapeutics also announced that Professor David Spring of the
Chemistry Department in the University of Cambridge has joined its
Scientific Advisory Board. David brings a wealth of experience from the
interface between biological systems and organic synthesis, with
specific application to drug discovery. He has had a distinguished
career, formally working with Sir Jack Baldwin in the University of
Oxford and Professor Stuart Schreiber in Harvard University.
Dr David Williams, CEO at Nanna Therapeutics, said:
“The Innovate UK funding will enable us to extend application of our
novel drug discovery platform and enable additional corporate growth.
Our aim is to address the growing need for effective medicines for
diseases associated with an ageing population and mitochondrial
dysfunction with a more efficient drug discovery process. It is
also a pleasure to welcome Professor David Spring, another supporter of
ultimately making the provision of cost-effective treatments for any
disease a reality, to our team.”
About Nanna Therapeutics
Nanna Therapeutics is developing breakthrough medicines for the
treatment of age-related diseases, focusing first on those linked to
mitochondrial dysfunction, including Parkinson’s disease and Amyotrophic
Lateral Sclerosis (ALS).
To this end, Nanna Therapeutics has built a unique, game-changing
platform that accelerates drug discovery by its ability to create
millions of novel compounds, functionally screen them at nanoscale in
multiple assays, including those with drug-like properties and toxicity,
integrating the huge datasets generated with machine learning to select
the best and safest drug molecules. This provides a paradigm shift in
the speed, efficiency and quality of drug discovery and dramatically
enhances safety profiling, with the goal to improve clinical success.
Nanna Therapeutics also works with strategic partners to develop novel
first-in-class medicines across all therapeutic areas.
Further information can be found at www.nannatherapeutics.com.
Contacts
Nanna Therapeutics Ltd.
David Williams, PhD
Chief
Executive Officer
Tel: +44(0)1223 423506
Email: info@nannatx.com
Halsin Partners (media)
Mike Sinclair
Partner
Tel:
+44 (0) 20 7318 2955
Email: msinclair@halsin.com